French ECLIPs™ Efficacy and Safety Investigation

Inclusion Criteria:

1. Patient whose age is greater than 18 years old

2. Patient with an unruptured or previously ruptured (at least 1 month from date ofrupture and with partial occlusion of the dome of the aneurysm by endovasculartechniques or by open neurosurgery, and in stable neurological condition-WFNS I andII with a good recovery to at least to mRS 0-2) saccular, intracranial aneurysm orrecurrent aneurysm, which arises at a bifurcation of Basilar Tip or Carotid Terminuswith a minimal diameter of 5mm and a maximal diameter <25mm, has a neck length of >4mm or dome:neck ratio <2, branch artery diameters in the range of 2.0mm to 3.25mm

3. Patient aneurysm arises at a bifurcation artery with at least one of the two branchartery vessels having a diameter between 2.0mm and 3.25mm

4. Patient understands the nature of the procedure and has the capacity to provideinformed consent (including fluency in French language)

5. Patient is willing to have on-site 30- day, 6-month, and 12 month follow-upevaluations as per standard clinical practice

Exclusion Criteria:

1. Patient with an aneurysm deemed to be an eligible candidate for surgical clipping bythe investigator

2. Patient who presents with an intracranial mass or currently undergoing radiationtherapy for carcinoma of the head or neck region

3. Major surgery within previous 30 days or planned in the next 120 days afterenrolment

4. Patient with an International Normalized Ratio (INR) ≥ 1.5

5. Patient with serum creatinine level ≥104 µmol/L (or 2.5mg/dL) at time of enrolment

6. Patient with a platelet count ˂100x103 cells/mm3 or known platelet dysfunction attime of enrolment

7. Patient who has a known cardiac disorder, likely to be associated withcardio-embolic symptoms such as atrial fibrillation

8. Patient with any condition that, in the opinion of the treating physician, wouldplace the participant at a high risk of embolic stroke or with any medicalco-morbidity likely to affect the outcome (e.g. pulmonary disease, uncontrolleddiabetes, blood disorders)

9. Patient with known allergies to nickel-titanium metal

10. Patient with known allergies to aspirin, heparin, ticlopidine, clopidogrel,prasugrel or other anti-platelet or P2Y12 agents or to general anesthesia

11. Subject has resistance to P2Y12 agents based on a validated platelet testing method (Verify Now, Multiplate or other)

12. Patient with a life threatening allergy to contrast (patients with itching or rashas a reaction to contrast can be included if properly prophylactically treated)

13. Patient with inappropriate anatomy as demonstrated by angiography due to severeintracranial vessel tortuosity or stenosis, or intracranial vasospasm not responsiveto medical therapy

14. Patient who is currently participating in another clinical research study involvingan investigational product

15. Patient who has had a previous intracranial procedure associated with the targetaneurysm such that access and placement of an eCLIPs™ device would be compromised

16. Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebralartery) or intracranial artery within 30 days prior to the treatment date

17. More than one intracranial aneurysm that requires treatment within 12 months.

18. Asymptomatic extradural aneurysms requiring treatment

19. Severe neurological deficit that renders the subject incapable of livingindependently

20. Unstable neurological deficit (i.e. worsening or improvement of clinical conditionin the last 30 days

21. Dementia or psychiatric problem that prevents the subject from completing requiredfollow up

22. Subject had a subarachnoid haemorrhage within 1 month prior to enrolment date

23. Subject has a non-treated arterio-venous malformation in the territory of the targetaneurysm

24. Subject has a need for long-term use of anticoagulants

25. Patient who is unable to complete the required follow-up

26. Inability to understand the study or history of non-compliance with medical advice

27. Evidence of active infection at the time of treatment

28. Patient who is pregnant or breastfeeding

29. Patient who has participated in a drug study within the last 30 days

30. Patient over the age of majority benefiting from legal protection (guardianship,curatorship, safeguard of justice)